Here are three things to know:
1. CartiHeal’s proprietary implant is designed for joint surface lesion treatment.
2. The first two U.S. patients were enrolled in the Agili-C Investigational Device Exemption pivotal study.
3. In Europe and Israel, 80 patients have been enrolled and treated in the study, which aims to demonstrate Agili-C’s superiority over microfracture and debridement to treat cartilage or osteochondral defects in the knee.
More articles on devices:
Life Spine reports device revenue growth: 3 details
25%+ of hip arthroscopy patients still get opioids 3 months after surgery: 5 things to know
DePuy Synthes, Medtronic, NuVasive & more: 9 device company notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
